Fecha de publicación: 09/08/2018 Fuente: WIPO "miel" The disclosure also provides compositions and methods related to combination therapy with HSP90 inhibitors and BCL-2 pathway inhibitors for treating cancer. The disclosure also provides compositions and methods related to the use of 'low dose' HSP90 inhibitors in the treatment of cancer, alone and in combination with other therapeutic agents.